MEDINA has implemented a series of in-vitro enzymatic and protein-protein interaction assays.
These assays are suitable for the identification of novel therapeutic small molecule inhibitors, natural products, or biologics against SARS-CoV-2 cellular entry, replication, or abnormal immune response.
Covid-19 -Virus Assays
Thermofluor High Throughput Screens, enzymatic degradation validation
- Automated screening of pure compound libraries in the 384-well plates miniaturized format by Thermofluor for the identification of Mpro de-stabilizers and stabilizers (DMSO tolerance 5%). Further characterization by dose-response experiments (Thermofluor) and functional confirmation by enzymatic peptide degradation monitored by Fluorescence Intensity in the 384 formats (DMSO tolerance 5%).
Homogeneous Time-Resolved FRET, sandwich ELISA
- Automated screening of ACE2/Spike inhibitors in the 384-well plates format by HTRF.
- Semi-automated screening of ACE2/Spike inhibitors in the 96-well plates format by sandwich ELISA.
Recombinant production of the targets, Thermofluor screens, TOM70/Orf9 PPI screens
- Recombinant production of the targets of interest for biophysical applications (fusions available GST-tag, His-tag, Flag-tag, Avi-tag). Screening of pure compound libraries in the 384-well plates miniaturized format by Thermofluor. Screening of pure compound libraries and microbial extracts under development (Time-Resolved technologies, 384-wells plates format).
